Scinai Immunotherapeutics Ltd. Financial Results Overview
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical firm dedicated to developing innovative biological products for inflammation and immunology as well as offering contract development and manufacturing organization (CDMO) services, released its financial results reflecting encouraging improvements.
Shareholder Equity Enhancement
In a recent development, Scinai successfully restructured its Loan Agreement with the European Investment Bank (EIB). This restructuring allowed the conversion of an outstanding loan of approximately EUR 26.6 million, equivalent to around $28.1 million, into equity. This strategic move elevated the company's shareholders' equity from a negative $7.3 million to a positive $10 million.
Details of Loan Conversion
The transaction involved issuing 1,000 no-par value preferred shares convertible into American Depositary Shares (ADS) representing 19.5% of the company's fully diluted capital stock. Under this arrangement, the EIB agreed not to convert these shares into ADS for a specified period, adding a safeguard for corporate equity integrity.
Regaining Nasdaq Compliance
Scinai's compliance with Nasdaq Listing Rule 5550(b)(1) has been reinstated thanks to this strategic financial maneuver. This rule mandates that companies maintain a minimum stockholders' equity of at least $2.5 million. The progression towards compliance showcases Scinai's commitment to strengthening its financial standing in a competitive market.
Growth in CDMO Services
The CDMO unit of Scinai has seen substantial growth since January of the current year, attaining work orders valued at approximately $600,000. This growth is expected to continue as the company engages in advanced discussions with potential clients, aiming for increased market presence.
Support from Grants
Scinai has also secured $575,000 in grants from the Israeli Innovation Authority, further supporting its CDMO business unit. This grant could potentially extend to an additional reimbursement of up to 66% of approved expenses, significantly aiding in operational costs.
Research and Development Updates
On the research front, the company has made notable strides in developing its flagship anti-IL-17A/F nanoAntibody, SCN-1. Positive feedback from the Paul Erlich Institute allows progression towards pivotal clinical trials planned for 2025.
Clinical Pipeline Development
In a recent advisory meeting, Scinai received critical guidance that positions the company favorably for future submissions to regulatory bodies, thereby enhancing its potential for innovative treatment solutions in the autoimmune disease segment.
Financial Summary for Nine Months Ending September 30, 2024
Scinai's financial performance over the nine months has marked significant changes: revenues reached $452,000. This is a substantial increase from the previous year, as the CDMO segment generated income for the first time. R&D expenses slightly decreased to $4.2 million from $4.6 million, while net income exhibited a remarkable turnaround from a loss of $4.17 million to a gain of $7.03 million.
Cash Position
As of September 30, 2024, cash and cash equivalents stood at $1.17 million, showcasing strategic management of resources amid expansion efforts.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is at the forefront of biopharmaceutical innovation, focusing on creating unique biological products for unmet medical needs while offering comprehensive CDMO services. The company leverages cutting-edge research and strategic collaborations to enhance its market offerings.
Company website: www.scinai.com
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
Frequently Asked Questions
What recent financial changes occurred at Scinai?
Scinai's shareholdings rose from a negative $7.3 million to a positive $10 million following a loan restructuring.
How much revenue did Scinai generate in recent months?
The company reported $452,000 in revenue during the nine-month period ending September 30, 2024.
What is the focus of Scinai's business units?
Scinai operates with two main focuses: developing biological therapeutic products and providing CDMO services.
When is Scinai's clinical trial expected to begin?
The anticipated start date for the clinical trial of a key product is slated for the second half of 2025.
What strategic partnerships is Scinai pursuing?
Scinai intends to establish partnerships to enhance its nanoAntibody projects and expand its CDMO business unit.
